DiaMedica Inc. Stock Toronto S.E.
Equities
DMA
CA25253T1075
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 128M 93.39M |
---|---|---|---|---|---|
Net income 2024 * | -37M -27.08M | Net income 2025 * | -47M -34.4M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.45
x | P/E ratio 2025 * |
-2.95
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
1st Jan change | Capi. | |
---|---|---|
-1.67% | 104B | |
+2.34% | 97.42B | |
+0.79% | 22.2B | |
-17.74% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-16.22% | 15.06B | |
+4.10% | 13.98B | |
+33.70% | 11.66B |
- Stock Market
- Equities
- DMAC Stock
- DMA Stock